CMAB Biopharma and Laekna Therapeutics Enter Strategic Agreement for LAE005 Global Development and Commercialization Partnership
- Thursday, September 10, 2020, 7:09
- Finance
- Add a comment
SUZHOU, China, Sept. 10, 2020 /PRNewswire/ — CMAB Biopharma (Suzhou) Inc. (“CMAB”), and Laekna Therapeutics Shanghai Co., Ltd. (“Laekna Therapeutics”), today announced a strategic collaboration agreement in Suzhou BioBAY for speedup of Immune Checkpoint Inhibitor (ICI) drug candidate to…
About the Author
adminasapcorp has written 41552 stories on this site.